Related Experiment Video
Updated: Sep 19, 2025
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER
Miao Wang1, Kehua Hu2, Yanping Gao1
1Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China.
Objective:
To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.
Materials And Methods:
We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.
Results:
BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).
Conclusion:
BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.
More Related Videos
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
